Methods and compositions for treatment of diabetes and dyslipidemia
Inventors
Khanna, Ish • Pillarisetti, Sivaram
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8623897-B2
Publication Date
2014-01-07
Expiration Date
Abstract
The invention is directed to novel compounds of Formula I: as well as its stereoisomers and/or pharmaceutically acceptable salts, for the treatment of diabetes and diabetes associated dyslipidemia.
Core Innovation
The invention relates to a composition comprising at least one compound according to Formula I, including its stereoisomers and/or pharmaceutically acceptable salts. The compound structures are defined by substituent selections for R1, R2, R3-R6, R7, L1, n1, n2, and Y1/Y2, and at least one of R3-R6 forms a cyclic ring of 3-8 carbon atoms or otherwise selected groups. L1 is a linear aliphatic chain optionally substituted by alkyl, branched alkyl, cycloalkyl, or aryl.
The structural scope is expanded through alternative structural definitions referenced as Formula II and Formula III, where the same stereoisomers and/or pharmaceutically acceptable salts are covered. The invention also includes tautomers and mixtures, as well as pharmaceutically acceptable compositions that include a pharmaceutically acceptable carrier.
The invention further provides a method of treatment by administering a therapeutically effective amount of at least one compound according to Formula I to treat insulin resistance, diabetes, and/or cardiovascular disease. Diabetes-associated dyslipidemia is addressed specifically in conjunction with Formula III as an indicated treatment target, and the embodiments include AMPK activators and inhibitors of lipid synthesis as functional embodiments connected with the claimed compound class.
Claims Coverage
The independent claims identified are directed to a composition defined by Formula I and a method of treatment by administering Formula I compounds. The main inventive features collectively comprise the defined Formula I structural framework, including stereoisomers and/or pharmaceutically acceptable salts, and its use for treating insulin resistance, diabetes, and/or cardiovascular disease, with diabetes-associated dyslipidemia tied to Formula III.
Formula I compound composition with constrained substituents
A composition comprising at least one compound according to Formula I, including stereoisomers and/or pharmaceutically acceptable salts, wherein substituent selections for R1, R2, R3-R6, R7, L1, n1, n2, and Y1/Y2 are defined; at least one of R3-R6 forms a cyclic ring of 3-8 carbon atoms or otherwise selected groups; L1 is a linear aliphatic chain optionally substituted by alkyl, branched alkyl, cycloalkyl, or aryl; and Y1/Y2 are constrained so that when Y2 is present both Y1 and Y2 are hydrogen, and when Y2 is not present Y1 forms a carbonyl group.
Treatment method by administering Formula I compounds
A method for the treatment of insulin resistance, diabetes, and/or cardiovascular disease in a subject, comprising administering at least one compound according to Formula I, including stereoisomers and/or pharmaceutically acceptable salts, with the same structural constraints on R1, R2, R3-R6, R7, L1, n1, n2, and Y1/Y2.
Overall, the independent claim set is directed to compositions and treatment methods that rely on compounds defined by Formula I with tightly constrained substituent and structural parameters, including a cyclic ring portion of 3-8 carbon atoms, a linear aliphatic chain, and Y1/Y2 forming either hydrogen(s) or a carbonyl group.
Stated Advantages
Documented Applications
Treatment of insulin resistance, diabetes, and/or cardiovascular disease in a subject by administering at least one compound according to Formula I, including stereoisomers and/or pharmaceutically acceptable salts.
Treatment of diabetes-associated dyslipidemia using compounds defined by Formula III.
Interested in licensing this patent?